Commentary - (2025) Volume 13, Issue 5
Received: 01-Oct-2025, Manuscript No. JCMG-26-185562;
Editor assigned: 03-Oct-2025, Pre QC No. P-185562;
Reviewed: 17-Oct-2025, QC No. Q-185562;
Revised: 22-Oct-2025, Manuscript No. R-185562;
Published:
29-Oct-2025
, DOI: 10.37421/2472-128X.2025.13.360
Citation: Rahman, Amir. ”RNA-Seq: Unlocking Disease Mechanisms for Personalized Treatments.” J Clin Med Genomics 13 (2025):360.
Copyright: © 2025 Rahman A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
RNA sequencing (RNA-Seq) stands as a transformative technology within the realm of medical genomics, offering unparalleled capabilities for comprehensive transcriptome analysis. Its pivotal role in identifying novel disease biomarkers and elucidating molecular disease mechanisms is critical for guiding personalized treatment strategies [1].
By precisely quantifying gene expression, detecting intricate alternative splicing events, and discovering diverse non-coding RNAs, RNA-Seq furnishes profound insights into cellular function and dysfunction across a spectrum of medical conditions, encompassing cancer, infectious diseases, and genetic disorders [1].
The application of RNA-Seq profoundly aids in patient stratification, the identification of therapeutic targets, and the meticulous monitoring of treatment responses [1].
This powerful technique has been instrumental in dissecting the complexity of metastatic breast cancer, particularly in identifying differentially expressed genes in response to novel therapeutic agents, thereby revealing key altered pathways that suggest potential mechanisms of action and resistance [2].
These findings are crucial for facilitating the selection of patient subgroups likely to derive maximum benefit from specific treatments, paving the way for the design of more targeted and effective clinical trials [2].
In the challenging landscape of non-small cell lung cancer, single-cell RNA sequencing (scRNA-Seq) has emerged as a revolutionary tool, providing unprecedented resolution to dissect cellular heterogeneity within tumors. This advanced approach enables the identification of distinct cell populations, including rare cancer stem cells and immunosuppressive myeloid cells, offering a detailed map of cellular interactions vital for developing sophisticated combination immunotherapies [3].
Furthermore, RNA-Seq has proven invaluable in the diagnosis and classification of rare genetic disorders, enabling researchers to uncover gene expression dysregulation that may elude detection by genomic sequencing alone. This transcriptomic profiling approach has been instrumental in identifying molecular signatures for previously undiagnosed diseases, thereby facilitating accurate diagnoses and informing crucial genetic counseling [4].
The efficacy of antiviral therapies for conditions such as Hepatitis C virus (HCV) is also significantly enhanced by RNA-Seq. Its application in monitoring host gene expression changes during treatment allows for a deeper understanding of pathways involved in viral clearance and treatment response, illuminating host-pathogen interactions and potential resistance mechanisms [5].
In the field of hematology, RNA-Seq has been employed to characterize the intricate transcriptomic landscape of acute myeloid leukemia (AML). This research has led to the identification of novel fusion transcripts and differentially expressed microRNAs associated with specific AML subtypes and prognoses, contributing to refined AML classification and the discovery of potential therapeutic targets [6].
The integration of RNA-Seq with spatial transcriptomics represents a significant advancement, offering a powerful approach to understanding the spatial organization of gene expression within tissues. This methodology enables the characterization of distinct cellular niches and their transcriptomic signatures within their native microenvironment, providing novel perspectives on disease progression and therapeutic intervention in complex tissues [7].
Moreover, RNA-Seq is actively utilized in identifying long non-coding RNAs (lncRNAs) as potential biomarkers for the early detection of colorectal cancer. Analysis has revealed specific lncRNAs with significantly altered expression levels in tumor tissues compared to adjacent normal tissues, underscoring their diagnostic potential [8].
Finally, RNA-Seq is employed to unravel the complex transcriptomic changes associated with drug resistance in ovarian cancer. This research has identified key gene expression signatures and pathway alterations that confer resistance to platinum-based chemotherapy, providing critical knowledge for developing strategies to combat or prevent drug resistance in patients [9].
RNA sequencing (RNA-Seq) has revolutionized medical genomics by enabling comprehensive transcriptome analysis, playing a crucial role in identifying novel disease biomarkers and understanding disease mechanisms at a molecular level to guide personalized treatment strategies [1].
It provides deep insights into cellular function and dysfunction in various medical conditions, including cancer, infectious diseases, and genetic disorders, by quantifying gene expression, detecting alternative splicing, and discovering non-coding RNAs [1].
Its applications extend to patient stratification, therapeutic target identification, and monitoring treatment response [1].
In the context of metastatic breast cancer, bulk RNA-Seq has proven effective in identifying differentially expressed genes in response to novel therapeutic agents, revealing key pathway alterations that suggest potential mechanisms of action and resistance [2].
These findings are instrumental in selecting patient subgroups likely to benefit from specific treatments, thereby facilitating the advancement of targeted clinical trials [2].
Single-cell RNA sequencing (scRNA-Seq) offers unprecedented resolution for dissecting cellular heterogeneity within tumors, as demonstrated in non-small cell lung cancer research [3].
This application allows for the identification of distinct cell populations, including rare cancer stem cells and immunosuppressive myeloid cells, providing essential detailed mapping of cellular interactions for the development of combination immunotherapies [3].
The utility of RNA-Seq in the diagnosis and classification of rare genetic disorders is significant, as it can uncover gene expression dysregulation not detectable through genomic sequencing alone [4].
This transcriptomic profiling approach has been instrumental in identifying molecular signatures for undiagnosed diseases, facilitating accurate diagnoses and informing genetic counseling [4].
RNA-Seq is also employed to monitor the efficacy of antiviral therapies for Hepatitis C virus (HCV) by assessing host gene expression changes during treatment [5].
This aids in identifying pathways involved in viral clearance and treatment response, offering a deeper understanding of host-pathogen interactions and potential resistance mechanisms [5].
In the study of acute myeloid leukemia (AML), RNA-Seq has been used to characterize its transcriptomic landscape, leading to the identification of novel fusion transcripts and differentially expressed microRNAs associated with specific AML subtypes and prognoses [6].
These findings contribute to refining AML classification and identifying potential therapeutic targets [6].
The integration of RNA-Seq with spatial transcriptomics provides a powerful approach for understanding the spatial organization of gene expression in tissues [7].
This method allows for the characterization of distinct cellular niches and their transcriptomic signatures within their native microenvironment, offering new perspectives on disease progression and therapeutic intervention in complex tissues [7].
Furthermore, RNA-Seq is utilized in identifying long non-coding RNAs (lncRNAs) as potential biomarkers for the early detection of colorectal cancer [8].
The analysis has revealed specific lncRNAs with significantly altered expression levels in tumor tissues compared to adjacent normal tissues, suggesting their diagnostic potential [8].
Finally, RNA-Seq is employed to understand the transcriptomic changes associated with drug resistance in ovarian cancer, identifying key gene expression signatures and pathway alterations that confer resistance to platinum-based chemotherapy [9].
This knowledge is critical for developing strategies to overcome or prevent drug resistance in patients [9].
RNA sequencing (RNA-Seq) is a pivotal technology in medical genomics for analyzing transcriptomes, identifying disease biomarkers, and understanding molecular mechanisms to guide personalized treatments. It quantifies gene expression, detects splicing events, and discovers non-coding RNAs, offering insights into cellular function in various diseases like cancer and genetic disorders. Specific applications include biomarker discovery for metastatic breast cancer, dissecting tumor microenvironment heterogeneity in lung cancer using single-cell RNA-Seq, and aiding in the diagnosis of rare genetic disorders by revealing gene expression dysregulation. RNA-Seq also monitors host responses to antiviral therapies for Hepatitis C, characterizes transcriptomic profiles of acute myeloid leukemia, and integrates with spatial transcriptomics to study tissue-level gene expression. Furthermore, it is used to identify long non-coding RNAs as early biomarkers for colorectal cancer and to understand drug resistance mechanisms in ovarian cancer, ultimately contributing to improved diagnostics and therapeutics across a range of medical conditions.
None
None
Journal of Clinical & Medical Genomics received 391 citations as per Google Scholar report
